Roche Reports Phase 3 Sefaxersen Data in IgA Nephropathy
Roche said investigational sefaxersen significantly reduced proteinuria in adults with IgA nephropathy in the Phase 3 IMAgINATION study.
Roche said investigational sefaxersen significantly reduced proteinuria in adults with IgA nephropathy in the Phase 3 IMAgINATION study.